Morgan Stanley Discount Zert NOVN.../ DE000MJ82FY8 /
1/10/2025 7:49:24 PM | Chg.- | Bid8:40:56 PM | Ask8:40:56 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
87.62EUR | - | 87.51 Bid Size: 125 |
87.55 Ask Size: 125 |
NOVARTIS N | - CHF | 12/28/2026 | Call |
GlobeNewswire
7/30/2024
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
7/8/2024
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
GlobeNewswire
6/26/2024
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
6/13/2024
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
GlobeNewswire
5/13/2024
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire
4/16/2024
Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthriti...
GlobeNewswire
4/11/2024
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Develo...
GlobeNewswire
3/14/2024
IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
GlobeNewswire
2/28/2024
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
2/28/2024
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invas...
GlobeNewswire
1/10/2024
Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for S...
GlobeNewswire
1/5/2024
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand ...